Corporate ActionJul 15, 2026, 04:51 PM
Encore Medical to Offer 3M Shares at $5.00 in IPO; Seeks NYSE American Listing
AI Summary
Encore Medical, Inc. filed an S-1/A for its initial public offering, planning to sell 3,000,000 shares of common stock at an expected price of $5.00 per share, aiming to raise $15.0 million. The company intends to use the estimated net proceeds of $10.6 million primarily to fund U.S. clinical trials for its PFO septal occlusion device for stroke and migraine indications, repay debt, and for general corporate purposes. Additionally, Encore Medical entered into an exclusive technology license agreement with GB Sciences for an AI platform, involving a $2.0 million cash payment and 1,000,000 shares upon IPO closing.
Key Highlights
- Initial Public Offering of 3,000,000 common shares at an expected price of $5.00 per share.
- Expected gross proceeds of $15.0 million; estimated net proceeds of $10.6 million.
- Applied for listing on NYSE American under the symbol "EMI".
- Entered exclusive AI technology license agreement with GB Sciences for $2.0M cash and 1M shares.
- Net loss of $(278,915) for Q1 2026; accumulated deficit of $7.1 million.
- Cash balance of $34,619 and order backlog of $1.0 million as of March 31, 2026.
- U.S. clinical trial for PFO septal occlusion device for stroke indication is underway.
Price Impact